Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · IEX Real-Time Price · USD
27.19
-0.06 (-0.22%)
Sep 23, 2022 4:00 PM EDT - Market closed
-0.22%
Market Cap 3.35B
Revenue (ttm) 112.42M
Net Income (ttm) -283.86M
Shares Out 123.35M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 636,696
Open 27.06
Previous Close 27.25
Day's Range 26.35 - 27.63
52-Week Range 20.24 - 56.08
Beta 1.70
Analysts Buy
Price Target 70.13 (+157.9%)
Earnings Date Nov 2, 2022

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotr... [Read more...]

Industry Biotechnology
IPO Date Dec 8, 2017
CEO Ryan Watts
Employees 395
Stock Exchange NASDAQ
Ticker Symbol DNLI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is 70.13, which is an increase of 157.93% from the latest price.

Price Target
$70.13
(157.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) a...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

3 weeks ago - GlobeNewsWire

3 Companies Growing Revenue Fast

S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past fiv...

Other symbols: ALKSNVAX
1 month ago - GuruFocus

Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus

Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.

1 month ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

1 month ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the...

3 months ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross ...

4 months ago - GlobeNewsWire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross ...

4 months ago - GlobeNewsWire

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) Up 7.4% Since Last Earnings Report: Can It Continue?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

7 F-Rated Stocks to Avoid During the Downturn

It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers. The post 7 F-Rated Stocks to Avoid During the Downturn appeare...

Other symbols: ATUSCSGPSSAMSMGW
6 months ago - InvestorPlace

Denali Therapeutics Inc. (DNLI) Moves 7.5% Higher: Will This Strength Last?

Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m...

6 months ago - Zacks Investment Research

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions t...

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros...

6 months ago - GlobeNewsWire

Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

6 months ago - Zacks Investment Research

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia...

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros...

6 months ago - GlobeNewsWire

Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

6 months ago - Zacks Investment Research

Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Misses Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st...

6 months ago - Zacks Investment Research

Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

6 months ago - GlobeNewsWire

Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program

As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinic...

7 months ago - Benzinga

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting ...

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

7 months ago - GlobeNewsWire

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...

7 months ago - GlobeNewsWire